Skip to main content
Kolinpharma logo

Kolinpharma — Investor Relations & Filings

Ticker · KIP ISIN · IT0005322950 LEI · 815600FC8F1A3BED2743 XMIL Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2019-11-13 Regulatory Filings
Country IT Italy
Listing XMIL KIP

About Kolinpharma

https://www.kolinpharma.com/index-en

Kolinpharma is a nutraceutical company established in 2013, specializing in the research and development of innovative products designed to improve well-being and quality of life. The company's core activities are centered on scientific research and product innovation, creating high-quality nutraceuticals. It operates an in-house R&D department and collaborates with leading universities for in-vitro and clinical studies. As a certified B Corporation, Kolinpharma adheres to high standards of social and environmental performance. The company distributes its proprietary branded products through a qualified network of medical-scientific representatives.

Recent filings

Filing Released Lang Actions
KOLINPHARMA PARTECIPA ALLA VI EDIZIONE DI IRTOP AIM INVESTOR DAY
Regulatory Filings Classification · 1% confidence The document is a formal communication dated November 13, 2019, originating from KOLINPHARMA S.p.A. The subject line ('Oggetto') clearly states: 'KOLINPHARMA PARTECIPA ALLA VI EDIZIONE DI "IRTOP AIM INVESTOR DAY"' (KOLINPHARMA PARTICIPATES IN THE 6TH EDITION OF "IRTOP AIM INVESTOR DAY"). The text confirms that the CEO will meet the financial community during this event and mentions that the institutional presentation will be made available on the company website. Since the document's primary purpose is to announce participation in an investor event where presentations will occur, and it explicitly states the presentation will be made available online, this fits the definition of a Report Publication Announcement (RPA) or a general regulatory announcement (RNS). Given the specific nature of announcing participation in an investor relations event, RPA is more precise than the general RNS fallback, as it signals the upcoming availability of related materials (the presentation). The document length (4848 chars) is short, supporting the 'announcement' classification over the full report itself.
2019-11-13 Italian
KOLINPHARMA-INTEGRAZIONE AL COMUNICATO DEL 16-10-19 ANNULLA E SOSTITUISCE PRECEDENTE
Earnings Release Classification · 1% confidence The document is an official notification from KOLINPHARMA S.p.A. dated October 22, 2019. The subject line indicates it is an 'INTEGRAZIONE AL SOSTITUISCE PRECEDENTE COMUNICATO DEL 16-10-19 ANNULLA E' (Integration to the press release published on 16-10-19 cancels and replaces the previous one). The content details a change in the company's share capital structure following the conversion of Price Adjustment Shares (PAS) into ordinary shares. This type of announcement, which modifies the total number of shares outstanding and reports on capital structure changes, aligns directly with the definition of 'Share Issue/Capital Change' (SHA). Although it is a regulatory filing (indicated by 'Informazione Regolamentata'), SHA is the more specific category for capital structure updates. FY 2018
2019-10-22 Italian
KOLINPHARMA-INTEGRAZIONE AL COMUNICATO STAMPA DEL 16-10-2019
Share Issue/Capital Change Classification · 1% confidence The document is an official communication from KOLINPHARMA S.p.A. dated October 21, 2019, titled 'KOLINPHARMA-INTEGRAZIONE AL COMUNICATO STAMPA PUBBLICATO IN DATA 16 OTTOBRE 2019' (Integration to the Press Release published on October 16, 2019). The content details an update regarding the conversion of Price Adjustment Shares (PAS) into ordinary shares following the achievement of EBITDA targets. This is a specific corporate action announcement related to share capital structure and shareholder information, issued as a press release/regulated information ('Informazione Regolamentata'). Since it specifically details changes in share ownership percentages following a corporate event (share conversion), it relates closely to capital structure changes or major shareholding notifications. However, the core event is the conversion of shares leading to a change in the shareholder structure, which is a form of capital change announcement. Given the options, 'Share Issue/Capital Change' (SHA) is a strong fit as it involves the conversion of performance shares into common stock, altering the capital structure. Alternatively, since it details the resulting shareholder composition, 'Major Shareholding Notification' (MRQ) could also be considered, but SHA covers the underlying mechanism (share conversion). Since the document explicitly details the change in the total number of shares held by key shareholders post-conversion, SHA is the most precise fit for the corporate action described.
2019-10-21 Italian
KOLINPHARMA-PUBBLICAZIONE STATUTO AGGIORNATO A SEGUITO CONVERSIONE PAS
Share Issue/Capital Change Classification · 1% confidence The document is an official communication from KOLINPHARMA S.p.A. dated October 16, 2019. The subject ('Oggetto') is 'KOLINPHARMA-PUBBLICAZIONE CONVERSIONE PAS' (Publication of PAS Conversion) and the text explicitly states that following the conversion of 180,000 Price Adjustment Shares (PAS) into ordinary shares, the company has updated its share capital and published the updated bylaws ('statuto') on its website. This action directly impacts the company's capital structure and governance documents (statute). Since the core event is a change in the number of shares and the resulting update to the corporate charter due to a pre-agreed mechanism (PAS conversion), it relates to capital structure changes. The most fitting category is 'Capital/Financing Update' (CAP), as it details the finalization of a financing/share structure mechanism. While it mentions the statute update, the primary driver and reported outcome is the change in the share count (1,639,571 ordinary shares) and capital, making CAP more specific than a general Governance (CGR) or Report Publication (RPA) filing, although RPA is a close secondary consideration if the focus was purely on the publication announcement. Given the detailed reporting of the capital change, CAP is selected.
2019-10-16 Italian
KOLINPHARMA OTTIENE IL TERZO BREVETTO IN USA
Regulatory Filings Classification · 1% confidence The document is an official communication from KOLINPHARMA S.p.A., identified by the header 'Informazione Regolamentata' (Regulated Information) and the filing date of October 14, 2019. The subject ('Oggetto') is 'KOLINPHARMA OTTIENE IL TERZO BREVETTO IN USA' (KOLINPHARMA OBTAINS THIRD PATENT IN USA). The content details the granting of a new patent in the U.S. for the product Xinepa®. This type of announcement, concerning intellectual property rights, business development, and market expansion, does not fit neatly into standard financial reports (10-K, IR, ER) or corporate governance filings (DEF 14A, CGR). It is a specific business update that is being formally disclosed to the market. Since it is a specific, material business announcement that isn't covered by other specific codes (like M&A, Capital Change, or Director's Dealing), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'LTR' if it were legal proceedings, but here it is a positive IP announcement. Given the options, RNS serves as the best catch-all for significant, non-standard regulatory disclosures.
2019-10-14 Italian
KOLINPHARMA SPA approva la Relazione Finanziaria Semestrale al 30 giugno 2019
Earnings Release Classification · 1% confidence The document is a press release from KOLINPHARMA S.p.A. announcing the approval of its half-year financial report (Relazione Finanziaria Semestrale) as of June 30, 2019. It provides key financial highlights (Revenue, EBITDA, Net Result, etc.) and business updates. While it contains substantive financial data, it is structured as an initial announcement of results (Earnings Release) rather than the full, formal interim report itself. The document explicitly states at the end that the full report will be made available on the company's website, confirming this is the 'menu' (announcement) and not the 'meal' (full report). H1 2019
2019-09-26 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.